An interventional study of Formaldehyde and NO2 (Exposure to indoor pollutants) and Placebo (Exposure to indoor pollutants) in Allergic Asthma and Allergy to House Dust Mite, sponsored by University Hospital, Strasbourg, France. Withdrawn at 1 site in France. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2015-03-27.
Sponsored by University Hospital, Strasbourg, France · Not applicable and Interventional
It seems that the aldehydes and NO2, at the levels found indoor, could be the aggravating factors for an allergic response. However this effect has not been demonstrated. The investigators plan to study the effect of exposure to standard doses of these pollutants on the bronchial reactivity as measured by bronchial challenge tests with dust mite extract in volunteers asthmatic, allergic to house dust mite.
3,920 studies on the registry are indexed under Asthma; 506 are open to participants now.
Browse Asthma studies →University Hospital, Strasbourg, France is the lead sponsor of 960 studies on the registry; 336 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
NO2 400 µg/m3
Other: Formaldehyde and NO2 (Exposure to indoor pollutants)
Formaldehyde 100 µg/m3
Other: Formaldehyde and NO2 (Exposure to indoor pollutants)
mixture of Formaldehyde and NO2
Other: Formaldehyde and NO2 (Exposure to indoor pollutants)
Other: Placebo (Exposure to indoor pollutants)
Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
This study is withdrawn, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France